Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience

doi:10.4254/wjh.v9.i1.48

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8750)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

505

WORD

447

HTML

3424

Figures (1-2)

155

Tables (1-3)

132

Sum=4663

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

541

Download

987

Sum=1528

Publishing Process of This Article

Item

Count

Browse

1214

Download

1345

Sum=2559

Jan 8, 2017 (publication date) through Apr 16, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Jan 8, 2017; 9(1): 48-56
Published online Jan 8, 2017. doi: 10.4254/wjh.v9.i1.48

Open in New Tab Full Size Figure Download Figure

Figure 1 Complete virological suppression and partial virological suppression at on treatment time points. The proportion of patients who achieve complete virological suppression (HBV DNA < 20 IU/mL) or partial virological suppression (HBV DNA 20-2000 IU/mL) while on tenofovir therapy. The number of patients followed up at each time point is recorded below the Time axis. HBV: Hepatitis B virus.

Open in New Tab Full Size Figure Download Figure

Figure 2 Survival analysis of the influence of treatment experience on complete virological suppression. A: Time to virological suppression according to duration of treatment, n = 92; B: Amongst treatment naïve patients n = 54; C: Treatment experienced patients, n = 37; D: Treatment experienced viraemic patients, n = 20. Number at risk describes the number of target group patients captured at each time period.

Citation: Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, Shaw G, Bell SJ, Desmond PV, Thompson AJ. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World J Hepatol 2017; 9(1): 48-56
URL: https://www.wjgnet.com/1948-5182/full/v9/i1/48.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i1.48